Loading...
Loading...
Omeros Corporation
today
announced positive data using OMS721, the lead human monoclonal antibody for
its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to
inhibit thrombus formation in an ex vivo pathophysiologic system of human
atypical hemolytic uremic syndrome (aHUS), a form of thrombotic
microangiopathy (TMA). TMAs are a family of rare, debilitating and
life-threatening disorders characterized by excessive thrombi (clots) in the
microcirculation of the body's organs, most commonly the kidney and brain.
OMS721 is currently in a Phase 2 clinical program evaluating the drug's
efficacy in treating TMAs, including aHUS.
The data announced today resulted from studies in a well-established
experimental model of TMA aimed at assessing the potential therapeutic
benefits of OMS721 in TMA using serum samples from aHUS patients with
different etiologies obtained during the acute phase of disease as well as
during remission. The studies were conducted by Prof. Giuseppe Remuzzi and
colleagues Marina Noris and Miriam Galbusera at the Mario Negri Institute for
Pharmacological Research in Bergamo, Italy, and the Clinical Research Center
for Rare Diseases "Aldo e Cele Dacco" of the same institute, a European center
for the study of TMA. The experimental model is based on the finding that sera
from aHUS patients promote the formation of thrombi on human microvascular
endothelial cells, the defining pathological feature of TMA.
The studies reported today showed that OMS721 significantly inhibited thrombus
formation when added to serum samples from aHUS patients obtained during the
acute phase of disease (p<0.01) as well as during remission (p<0.0001). OMS721
was as effective at inhibiting thrombus formation as the positive control in
the studies – soluble complement receptor 1, an agent that completely blocks
the complement system.
Earlier this year, Omeros reported that OMS721 also significantly inhibited
complement deposition compared to control treatment in an experimental ex vivo
pathophysiologic system of complement activation in TMA, again using serum
samples from aHUS patients obtained during the acute phase of disease (p<0.01)
and during remission (p<0.001). Prof. Remuzzi's laboratories have previously
shown in the same complement-activation model that eculizumab (Soliris^®), a
monoclonal antibody blocking the complement factor C5 that is approved by the
FDA and the European Medicines Agency to treat patients with aHUS, also
inhibited complement deposition. Data recently published indicate that the ex
vivo pathophysiologic system established by Prof. Remuzzi and his colleagues
may be useful in assessing the clinical effectiveness of anti-complement
therapy in aHUS (Noris et al., Blood (2014) 124:1715).
"We believe that the notable anti-complement and anti-thrombotic activities of
OMS721 in serum samples from aHUS patients bode well for the therapeutic
potential of OMS721 in thrombotic microangiopathies," stated Prof. Remuzzi,
MD, FRCP, Research Coordinator at the Mario Negri Institute and international
expert in the study of kidney disease who has contributed major advances to
the understanding of the pathophysiology of hemolytic uremic syndrome.
Having demonstrated that the lectin pathway, and MASP-2 specifically, are
involved in the pathophysiology of aHUS, Prof. Remuzzi and his team are
currently conducting additional experiments to understand the mechanism by
which OMS721 blocks ex vivo thrombus formation in aHUS and its effect on
endothelial cells, platelets and the alternative pathway of complement.
"Thrombus formation is the central pathological feature of aHUS and other
TMAs, so we are particularly pleased with the robust anti-thrombotic activity
in serum samples from aHUS patients," stated Gregory A. Demopulos, M.D.,
chairman and chief executive officer of Omeros. "We believe that these most
recent data from Prof. Remuzzi's laboratories meaningfully de-risk our '721
Phase 2 program in TMAs, including aHUS, and we look forward to reporting
preliminary efficacy and safety data from the ongoing clinical trial."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in